诺泰生物: 国浩律师（杭州）事务所关于江苏诺泰澳赛诺生物制药股份有限公司2024年年度股东大会法律意见书

Group 1 - The legal opinion letter confirms the legality and validity of the convening and holding procedures of the 2024 Annual General Meeting of Jiangsu Nuotai Aosaikeno Biopharmaceutical Co., Ltd [2][14] - The meeting was convened in accordance with the relevant laws and regulations, including the Company Law and the rules set by the China Securities Regulatory Commission [4][14] - The meeting was held on May 23, 2025, at a specified location, and included both on-site and online voting methods [5][14] Group 2 - A total of 161 participants attended the meeting, representing 117,810,044 shares, which is 52.39% of the total voting shares [6][14] - The meeting included shareholders, their proxies, and company directors, all of whom met the qualifications to attend [6][14] - The voting results showed overwhelming support for the proposed resolutions, with over 99% approval from attendees [8][14] Group 3 - The resolutions discussed at the meeting included ten special resolutions requiring a two-thirds majority for approval, while other resolutions required a simple majority [7][14] - The voting process was conducted in accordance with the established rules, ensuring transparency and compliance with legal standards [14] - The final voting results confirmed that all resolutions were passed, validating the meeting's outcomes [14]